Please upgrade your browser.
Angiogenesis-related biomarkers regulated by hypoxia were found to be strong predictors of primary renal tumor response (PRT), progression-free survival (PFS), and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who were being treated with sunitinib prior to kidney removal, according to research published in Clinical Cancer Research.1
Ablation is a minimally invasive procedure that uses targeted radiation to kill tumors. This technique is prolonging survival rates for kidney cancer patients.
Twenty-two weeks into her third pregnancy, Jessica Dykstra experienced incredible joy and intense fear --- in just a few minutes. Jessica learned she was having a baby girl to complement her two toddler boys. And just minutes before, the 25-year-old San Diego resident was diagnosed with stage 2 renal cell carcinoma — a malignant tumor on her left kidney.
The Kidney Cancer Association’s strong financial health and commitment to accountability and transparency has earned it a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. “People can donate to our charity with confidence. We scored 100 percent in accountability and transparency,” said Bill Bro, vice president of the Kidney Cancer Association. Since 2002, using objective analysis, Charity Navigator has awarded only the most fiscally responsible organizations a 4-star rating. In 2011, Charity Navigator added 17 metrics, focused on governance and ethical practices as well as measures of openness, to its ratings methodology. These accountability and transparency metrics, which account for 50 percent of a charity’s overall rating, reveal which charities operate in accordance with industry best practices and whether they are open with their donors and stakeholders. On June 1, 2016, Charity Navigator upgraded its methodology for rating each charity's financial health with "Charity Navigator 2.1" to further substantiate the financial health of its four star charities. “We are proud to announce that the Kidney Cancer Association has earned our fourth consecutive 4-star rating. This is our highest possible rating and indicates that the organization adheres to sector best practices and executes its mission in a financially efficient way,” said Michael Thatcher, president and CEO of Charity Navigator. “Attaining a 4-star rating verifies that the Kidney Cancer Association exceeds industry standards and outperforms most charities in their area of work. Only 14 percent of the charities we evaluated have received at least 4 consecutive 4-star evaluations, indicating that the Kidney Cancer Association outperforms most other charities in America. This exceptional designation from Charity Navigator sets the Kidney Cancer Association apart from its peers and demonstrates to the public its trustworthiness.” About the Kidney Cancer Association: The Kidney Cancer Association, www.kidneycancer.org, is the world’s first international charity dedicated specifically to the eradication of death and suffering from renal cancers. It is also by far the largest kidney cancer charity, with members in more than 100 countries. We fund, promote and collaborate with the National Cancer Institute (NCI), American Society for Clinical Oncology (ASCO), American Urological Association (AUA) and other institutions on research projects. We educate families and physicians and serve as an advocate on behalf of patients at the state and federal levels in the United States and globally. About Charity Navigator Charity Navigator, www.charitynavigator.org, is the largest charity evaluator in America and its website attracts more visitors than all other charity rating groups combined. The organization helps guide intelligent giving by evaluating the Financial Health and Accountability & Transparency of more than 8,000 charities. Charity Navigator accepts no advertising or donations from the organizations it evaluates, ensuring unbiased evaluations, nor does it charge the public for this trusted data. As a result, Charity Navigator, a 501 (c) (3) public charity itself, depends on support from individuals, corporations and foundations that believe it provides a much-needed service to America's charitable givers. Charity Navigator, can be reached directly by telephone at (201) 818-1288, or by mail at 139 Harristown Road, Suite 101, Glen Rock, N.J., 07452.
The addition of cytoreductive nephrectomy to treatment with sunitinib malate did not provide a survival benefit for intermediate and poor-risk patients with metastatic renal cell carcinoma, according to results of the phase 3 CARMENA clinical trial presented at ASCO Annual Meeting.
We’ve taken part in the #ReadyRaiseRise movement with Bristol Myers Squibb to help raise money for advocacy groups like us. Now, it’s your turn. Rising up to #cancer takes a unique inner power - what’s yours? Show us by joining the Pic Your Power challenge. https://www.facebook.com/DiscoverIO
In a new study, researchers have found that miRNA processing mutations exhibit higher levels of Pleomorphic adenoma gene 1 (PLAG1), a protein that normally functions during development to turn on IGF2 expression. In kidney cells with miRNA mutations, PLAG1 levels are abnormally high, leading to inappropriate production of IGF2, which in turn promotes Wilms tumor formation.
Heating metals to very high temperatures can be incredibly dangerous for the 111 million people around the world who weld. The culprits are welding fumes, as well as exposure to radiation and asbestos, according to scientists at the International Agency for Research on Cancer. These toxins can potentially cause lung cancer, kidney cancer, and melanoma of the eye, as well as other health problems.
Obesity is associated with development of clear cell and possibly chromophobe renal cell carcinoma (RCC), but not papillary RCC, according to researchers.
Martin H. Voss, M.D., discusses the positive results of the CABOSUN trial.
|Powered by NeonCRM|